![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh5ngtS-a2z399aOT92Z2N4z_PJOkht5A4N038_Tr-oshJ7FLjEe-zkYuq2iC-pHWD7T6GnWPcwuNL4-7sRDQ2WS4yjXxd2RTtTX6_15CZIpa01Vp7ALaEgRUEojBdMVh4BUNZpLKiSDt8X/s320/ZYME2021052620210618-703975.png)
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
http://www.priceseries.com/trade/ZYME-Zymeworks-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2021052620210618.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments